# A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Source: https://onco.cc/trials/nct07143604/  
OnCo record `nct07143604` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AZD0901 in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 is a phase 2 interventional study registered as NCT07143604 by AstraZeneca, with 33 participants enrolled, started 2025-08-29 and due to reach its primary completion in 2026-09-28. Interventions recorded: AZD0901.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07143604
- Phase: 2
- Setting: A Phase II, Multicentre, Open-label, Single-arm Study of AZD0901 Monotherapy in Second-or Later-Lines Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- Sponsor: AstraZeneca
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT07143604: https://clinicaltrials.gov/study/NCT07143604

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07143604.json